Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008945 | 0.83 | KMT2A (0.76) | KMT2AMEN1GPR55NPC1MAPT | |
| SCHEMBL12008885 | 0.76 | KMT2A (0.80) | KMT2AMEN1GPR55NPC1MAPT | |
| SCHEMBL12008981 | 0.76 | FFAR1 (0.78) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008880 | 0.75 | FFAR1 (0.73) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008949 | 0.74 | KMT2A (0.79) | KMT2AMEN1GPR55NPC1MAPT | |
| SCHEMBL12006886 | 0.73 | FFAR1 (0.81) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008952 | 0.73 | FFAR1 (0.70) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008989 | 0.73 | FFAR1 (0.69) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008830 | 0.73 | FFAR1 (0.66) | FFAR1KMT2AMEN1GPR55NPC1 | |
| SCHEMBL12008943 | 0.72 | KMT2A (0.84) | KMT2AMEN1GPR55NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | FFAR1 2541/4885KMT2A 4591/4885MEN1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.